Labcorp stock holds above $330 as HSBC lifts its price target

Labcorp Holdings Inc. (US50540R4092) stock is trading in the mid-$330 range as of the recent New York close on August 21, 2026, with investors reacting to a new $330 price target that points to steady confidence in the company’s earnings power.

Price target lifted as shares extend 2026 gains

Per a detailed market overview reported on August 24, 2026, Labcorp closed at $336.34 on the New York Stock Exchange on August 21, 2026, marking a 2026 year-to-date gain of 34.06 percent and a five-day increase of 1.06 percent. The same overview also shows an average analyst target of $337.75, only slightly above the latest close, suggesting that the stock is already trading close to consensus expectations.

The fresh $330 price target, highlighted in that August 24, 2026 market summary as an upward adjustment from a prior $270 level, underscores how analyst views have shifted positively during 2026. The same report implies that the new target now sits just under the recent market price, a sign that part of the anticipated improvement in Labcorp’s earnings and cash flows has already been priced in.

2026 performance and valuation context

With the stock up 34.06 percent since January 1, 2026 according to the August 24, 2026 data snapshot, Labcorp has delivered a strong run that outpaces many large-cap healthcare names and positions the shares toward the upper end of their 52-week performance band. A static price chart for the Cboe listing shows Labcorp quoted at $336.38, with a five-day change of 1.07 percent and a year-to-date change of 5.78 percent for that venue; the differing year-to-date figure reflects the limited history of this specific chart rather than the full NYSE record but still confirms the stock’s upward bias.

The small gap between the $336.34 NYSE close and the $337.75 average target, as reported in the August 24, 2026 analyst overview, gives investors a concrete comparison point: the stock trades less than $1 below the consensus target, indicating limited upside under current assumptions but also reinforcing that recent gains are supported by the prevailing earnings outlook. The same data set suggests that the new $330 target is part of a broader cluster of expectations around the mid-$330 range.

Labcorp’s diagnostics and drug development platform

Labcorp Holdings Inc. operates as a global life sciences company with a broad portfolio of diagnostic testing, central laboratory services, and drug development support. While the detailed segment breakdown for the most recent quarter is not included in the August 24, 2026 market-data sources, Labcorp’s business model combines routine clinical laboratory services with specialized testing and clinical trial support, giving the company exposure to both steady testing demand and innovation-driven pharmaceutical pipelines.

In practice, Labcorp’s platform supports physicians, hospitals, and biopharmaceutical companies by providing laboratory testing, specimen management, and analytical services that help diagnose disease, monitor therapy, and advance new treatments through clinical research. This mix of recurring diagnostic revenue and project-based development work is central to how investors think about the company’s earnings resilience and growth potential, especially when analyst targets move higher as they have in 2026.

Representative service: comprehensive diagnostic testing

A representative offering within Labcorp’s portfolio is its comprehensive diagnostic testing service, which covers everything from routine blood panels and chemistry tests to advanced molecular assays and genomics-based diagnostics. These services are ordered by clinicians to support patient care decisions and are processed through Labcorp’s network of laboratories and patient service centers, forming the backbone of the company’s recurring revenue stream and helping to stabilize earnings across economic cycles.

Stock level anchored in the mid-$330 range

As of the August 21, 2026 NYSE close, Labcorp stock is quoted at $336.34, denominated in USD and reflecting regular-session trading on the New York Stock Exchange. The same August 24, 2026 data summary shows that the shares have gained 1.06 percent over the last five trading days, with a 34.06 percent increase since the start of 2026, signaling that the stock is consolidating gains substantially above its early-year levels while trading close to prevailing analyst targets.

Fact box

Company: Labcorp Holdings Inc.

ISIN: US50540R4092

Ticker: LH

Exchange: New York Stock Exchange

Price (as of August 21, 2026, 4:00 p.m. ET): $336.34 USD

Sector / Industry: Health care - diagnostics and research

Index membership: S&P 500